New Mexico Cancer Research Alliance

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2002

Legal Domicile

Principal Officer

CAROLYN MULLER

Phone

5052727799

Tax Period

2024-07-01 to 2025-06-30

New Mexico Cancer Research Alliance, founded in 2002, is a community nonprofit in the Medical Research sector that reported $2.5M in total revenue in fiscal year 2024. Revenue surged 21% from the prior year, signaling strong growth momentum. The organization ran a surplus of $472K, a strong 19% operating margin.

Mission

TO PROVIDE NEW MEXICO CANCER PATIENTS AND THEIR FAMILIES ACCESS TO THE LATEST RESEARCH, TECHNOLOGIES, AND CLINICAL SERVICES IN PREVENTION, SCREENING, DETECTION, DIAGNOSIS/STAGING, TREATMENT, SUPPORTIVE CARE, AND CONTINUED SURVEILLANCE THROUGH COLLABORATION AMONG PUBLIC AND PRIVATE HEALTHCARE PROVIDERS.

Program Service Accomplishments

Program 1

Expenses: $1,007,541 Revenue: $195,718

THE ORGANIZATION PROVIDES NEW MEXICO CANCER PATIENTS AND THEIR FAMILIES ACCESS TO THE LATEST RESEARCH, TECHNOLOGIES, AND CLINICAL SERVICES IN PREVENTION, SCREENING, DETECTION, DIAGNOSIS/STAGING...

THE ORGANIZATION PROVIDES NEW MEXICO CANCER PATIENTS AND THEIR FAMILIES ACCESS TO THE LATEST RESEARCH, TECHNOLOGIES, AND CLINICAL SERVICES IN PREVENTION, SCREENING, DETECTION, DIAGNOSIS/STAGING, TREATMENT, SUPPORTIVE CARE, AND CONTINUED SURVEILLANCE THROUGH COLLABORATION AMONG PUBLIC AND PRIVATE HEALTHCARE PROVIDERS. CANCER CLINICAL TRIALS ENABLE PATIENTS TO BETTER UNDERSTAND AND PARTICIPATE IN THE MANAGEMENT OF THEIR DISEASE. THE ORGANIZATION'S MAIN SOURCES OF SUPPORT AND REVENUE ARE RECEIVED FROM CLINICAL TRIALS SPONSORS AND CONTRIBUTIONS. DURING THE FISCAL YEAR ENDING JUNE 30, 2025, APPROXIMATELY 270 PATIENTS AND THEIR FAMILIES WERE ASSISTED.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2024)

Revenue Breakdown

Contributions & Grants $2,292,267

Program Service Revenue $195,718

Investment Income $19,582

Other Revenue $0

TOTAL REVENUE $2,507,567

Expense Breakdown

Grants Paid $0

Salaries & Benefits $37,624

Fundraising Expenses $0

Program Expenses $1,007,541

Other Expenses $1,997,948

TOTAL EXPENSES $2,035,572

Year-over-Year Comparison

	2024	2023	Change
Revenue	$2,507,567	$2,073,590	+0.2%
Expenses	$2,035,572	$1,999,782	+0.0%
Net Income	$471,995	$73,808	+5.4%

Key Indicators

✗ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✗ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

N/A

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✗ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

✗ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

Total Directors

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
MICHELE GOODMAN	CO-CHAIR	1.00	Officer Director	$0	$0	$0
CAROLYN MULLER MD	CO-CHAIR	1.00	Officer Director	$0	$0	$0
KRISTIN GATES	SEC/TREASURER	0.50	Officer Director	$0	$0	$0
Jessica Valdez MD	Director	0.50	Director	$0	$0	$0
ETHAN BINDER MD	DIRECTOR	0.50	Director	$0	$0	$0
WILLIAM ADLER MD	DIRECTOR	0.50	Director	$0	$0	$0
BERNARD AGBEMADZO MD	DIRECTOR	0.50	Director	$0	$0	$0
URSA BROWN-GLABERMAN MD	DIRECTOR	0.50	Director	$0	$0	$0
XIAXIN LI MD	DIRECTOR	0.50	Director	$0	$0	$0
Neda Hashemi MD	Director	0.50	Director	$0	$0	$0
CALVIN RIDGEWAY MD	DIRECTOR	0.50	Director	$0	$0	$0
ANDREW SUSSMAN PhD	DIRECTOR	0.50	Director	$0	$0	$0
CHRISTIE WHITE	DIRECTOR	0.50	Director	$0	$0	$0
CHARLES WIGGINS PhD	DIRECTOR	0.50	Director	$0	$0	$0

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2025	$2,507,567	$2,035,572	$1,205,422	$471,995
2024	$2,073,590	$1,999,782	$920,942	$73,808
2023	$1,431,885	$1,572,648	$1,178,582	$-140,763
2022	$1,476,963	$1,831,039	$985,027	$-354,076
2021	$1,559,732	$1,535,360	$1,797,430	$24,372
2020	$2,197,012	$2,665,372	$2,011,753	$-468,360
2019	$2,946,750	$3,085,776	$2,620,364	$-139,026
2018	$3,350,122	$3,364,448	$2,816,618	$-14,326